ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AUPH vs VERA // 10Y YIELD & FRED MACRO BETA

Aurinia Pharmaceuticals Inc (NASDAQ) VS. Vera Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: AUPH 3 — VERA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. VERA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AUPH VERA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 16.50% -35.00% +51.50 AUPH /roic <GO>
EV/EBITDA & P/E Valuation 21.1x — — TIE /valuation <GO>
Free Cash Flow Yield 5.92% -10.99% +16.91 AUPH /fcf-yield <GO>
Operating Margin 37.10% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 20.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.33 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 AUPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 52.7 -3.60 VERA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.22B $2.23B -$17.2M VERA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AUPH REV VERA REV AUPH GROSS % VERA GROSS % AUPH FCF VERA FCF
FY 2025 $283.1M $0 88.5% — $135.7M -$241.7M
FY 2024 $235.1M $0 88.0% — $44.4M -$135.7M
FY 2023 $175.5M $0 — — -$33.5M -$92.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
VERA // BETA —